Loading
IMforte produced the first maintenance treatment ever approved for extensive-stage small-cell lung cancer, adding lurbinectedin to the immunotherapy that continues after chemotherapy.
IMforte, trial NCT05091567 sponsored by Roche, Jazz and PharmaMar and reported at the ASCO 2025 plenary and in the Lancet in 2025, produced the first maintenance treatment ever approved for extensive-stage small-cell lung cancer, adding lurbinectedin to the atezolizumab that continues after chemotherapy. It randomised 483 patients without progression after four cycles of carboplatin, etoposide and atezolizumab to lurbinectedin plus atezolizumab or atezolizumab alone, met both primary endpoints of overall and progression-free survival, and led to FDA approval on 2 October 2025, at the cost of added myelosuppression and fatigue. The maintenance concept is now being tested with tarlatamab in DeLLphi-305, so which agent wins the maintenance slot is the open question.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
483 enrolled.
| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Overall survivalprimary | Lurbinectedin + atezolizumab | 242 | 13.2 months | 0.73 (0.57 to 0.95) | - | link |
| Atezolizumab | 241 | 10.6 months | ||||
| Progression-free survival (IRF)primary | Lurbinectedin + atezolizumab | - | 5.4 months | 0.54 (0.43 to 0.67) | - | link |
| Atezolizumab | - | 2.1 months |
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Lurbinectedin, Jazz Pharmaceuticals, Extensive-stage small-cell lung cancer, Small-cell lung cancer.
Shares Lurbinectedin basket trial, small-cell lung cancer cohort, PharmaMar, Lurbinectedin, Jazz Pharmaceuticals.
Shares Lurbinectedin, Jazz Pharmaceuticals, Small-cell lung cancer, Cytotoxic chemotherapy.
Shares PharmaMar, Lurbinectedin, Cytotoxic chemotherapy.
Shares Lurbinectedin, Extensive-stage small-cell lung cancer, Atezolizumab, Small-cell lung cancer.
Shares Lurbinectedin, Jazz Pharmaceuticals, Cytotoxic chemotherapy.
Shares Chemo-immunotherapy induction → maintenance intensification (SCLC), Extensive-stage small-cell lung cancer, Lung cancer (all types), Small-cell lung cancer.
Shares Lurbinectedin, Extensive-stage small-cell lung cancer, Atezolizumab, Small-cell lung cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/